| pubmed-article:20856894 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20856894 | lifeskim:mentions | umls-concept:C0007124 | lld:lifeskim |
| pubmed-article:20856894 | lifeskim:mentions | umls-concept:C0025250 | lld:lifeskim |
| pubmed-article:20856894 | lifeskim:mentions | umls-concept:C1366499 | lld:lifeskim |
| pubmed-article:20856894 | lifeskim:mentions | umls-concept:C1515670 | lld:lifeskim |
| pubmed-article:20856894 | lifeskim:mentions | umls-concept:C0205251 | lld:lifeskim |
| pubmed-article:20856894 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:20856894 | pubmed:dateCreated | 2010-9-21 | lld:pubmed |
| pubmed-article:20856894 | pubmed:abstractText | Optimal management of breast ductal carcinoma in situ (DCIS) is controversial, and many patients are still overtreated. The local death of myoepithelial cells (MECs) is believed to be a pre-requisite to tumor invasion. We thus hypothesized that loss of CD10 expression, a MEC surface peptidase, would signify basement membrane disruption and confer increased risk of relapse in DCIS. The aim of our study was to retrospectively evaluate the prognostic value of CD10 in DCIS. | lld:pubmed |
| pubmed-article:20856894 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20856894 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20856894 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20856894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20856894 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20856894 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20856894 | pubmed:issn | 1932-6203 | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:PaesmansMaria... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:PiccartMartin... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:SotiriouChris... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:DurbecqVirgin... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:LarsimontDeni... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:RouasGhizlane... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:Haibe-KainsBe... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:TjalmaWiebren... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:AltintasSevil... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:DoriathValéri... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:ToussaintJérô... | lld:pubmed |
| pubmed-article:20856894 | pubmed:author | pubmed-author:BedardPhilipp... | lld:pubmed |
| pubmed-article:20856894 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20856894 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:20856894 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20856894 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:meshHeading | pubmed-meshheading:20856894... | lld:pubmed |
| pubmed-article:20856894 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20856894 | pubmed:articleTitle | Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). | lld:pubmed |
| pubmed-article:20856894 | pubmed:affiliation | Breast Cancer Translational Research Laboratory JC Heuson, Jules Bordet Institute, Brussels, Belgium. | lld:pubmed |
| pubmed-article:20856894 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20856894 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:4311 | entrezgene:pubmed | pubmed-article:20856894 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20856894 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20856894 | lld:pubmed |
